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Although it has been about 30 years since the discovery of circular RNAs (circRNAs)
in mammalian cells, these subtypes of RNAs’ capabilities have come into focus in
recent years. The unique structure and various functional roles of circRNAs in many
cellular processes have aroused researchers’ interest and raised many questions about
whether circRNAs can facilitate the diagnosis and treatment of diseases. To answer
these questions, we will illustrate the main known functions and regulatory roles of
circRNAs in the cell after presenting a brief history of the discovery of circRNAs and
the main proposed theories of the biogenesis of circRNAs. Afterward, the practical
application of circRNAs as biomarkers of different pathophysiological conditions will be
discussed, mentioning some examples and challenges in this area. We also consider
one of the main questions that human beings have always been faced, “the origin of life,”
and its possible connection to circRNAs. Finally, focusing on the various capabilities of
circRNAs, we discuss their potential therapeutic applications considering the immunity
response toward exogenous circRNAs. However, there are still disputes about the exact
immune system reaction, which we will discuss in detail.
Keywords: circRNA, biomarker, biological function, molecular therapy, protein-coding, immunity response, origin
of life
INTRODUCTION
Our current knowledge of the role and importance of circRNAs in mammals, including humans,
has come a long way. Since the first circular form of RNA was found in plant-infected viroids
(uncoated RNA molecules that infect certain higher plants), scientist’s views on circRNAs have
undergone tremendous changes, thanks to the development of new high-throughput sequencing
techniques. Sanger et al. (1976) confirmed that viroids like PSTVd are single-stranded RNA
molecules with a circular structure, based on the evidence from electron microscopic observations
and biochemical investigation.
Nigro et al. (1991) announced the presence of circular forms of tumor suppressor gene,
DCC (deleted in colorectal cancer). They referred to this finding merely as “scrambled exon”
(Nigro et al., 1991).
The fluctuations in the circRNA discovery area continued until changes in the conventional
algorithms and library preparation methods for RNA-seq in 2012, revealing the global expression
of circRNAs in the mouse brain and different cell types (Salzman et al., 2012). The tissue-specificity
and conserved expression of circRNAs mentioned in two separate published papers in 2013 revealed
their functional role in cells (Jeck et al., 2013; Salzman et al., 2013). Since then, researchers
have studied circRNAs from different angles to reveal this group of RNAs’ exact function and
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characteristics (More details on the history behind the evolution
of circRNAs researches are presented in Figure 1).
Herein we summarize the known and unknown issues about
circRNAs. The possible biogenesis models, roles in different
pathologies, and the biological functions of circRNAs have
been reviewed earlier (Salzman, 2016; Haddad and Lorenzen,
2019), so we overview these subjects briefly and from different
perspectives. This review’s primary focus is on the potential
applications of circRNAs, especially in the diagnosis and
treatment of diseases, and the findings of studies on the
possible immune system response toward the transfection of
exogenous circRNAs. Although there are still many unknown
issues in circRNAs’s field of research, it is likely that in the
near future, given the characteristics of circRNAs and the spread
of knowledge in this field of study, a number of the main
challenges facing scientists may be addressed, especially in the
treatment of diseases.
RNA BINDING PROTEINS, THE MAIN
CONTRIBUTORS OF CIRCRNAS
BIOGENESIS
The precise mechanism of circRNAs biogenesis is still a point
of discussion. Although spliceosome appears to be the main
actor of circRNA biogenesis, this process’s details remained
unclear. The two highlighted mechanisms recommended by the
researchers are direct backsplicing and exon skipping (lariat
model). In the direct backsplicing model, there are inverted
repeats in the vicinity of the exons. The base pairing of inverted
repeats leads to forming a stem-loop structure, which brings
circRNA-forming exons into proximity, thus enhancing the
interaction between donor splice-site and upstream acceptor
site (instead of downstream acceptor site in canonical splicing)
(Figure 2A). Backsplicing seems to be a rare phenomenon
due to the lower energy efficiency than canonical splicing
and the need for complementary sequences that initiate the
backsplicing process by bringing the splice sites close to
each other (Zhang et al., 2016). Emerging shreds of evidence
suggest that the complementary sequence is not enough for
circularization, and backsplicing is assisted by many RNA
binding proteins (RBPs).
One of the most prominent RBPs contributing to the
biogenesis of circRNAs is the splicing factor, namely Quaking
(QKI). QKI, which is a member of the STAR family (a
gene family involved in signal transduction and activation
of RNA), binds to conserved binding sites in the introns
adjacent to the circularization location and seems to catalysis the
circularization process by dimer formation (Vernet and Artzt,
1997; Conn et al., 2015).
Muscleblind (MBL) -examined in Drosophila- is another
splicing factor involved in circRNA’s biogenesis. MBL acts in
a cis manner and binds to its conserved binding sites, and
promotes the synthesis of circMbl, the most abundant circRNA
in the Drosophila’s head. The feedback loop occurring in this
process is remarkable. The MBL protein -synthesized from a
linear Mbl transcript- helps create circular Mbl and prevents
linear counterpart formation by competition with the canonical
splicing (Ashwal-Fluss et al., 2014).
NF90/NF110, double-strand binding proteins originating
from the ILF3 gene, also contribute to the backsplicing process.
Studies indicated that circRNA’s overall expression decreases
during viral infection, partly due to these antiviral operators’
nuclear export. Experiments such as the biotin-labeled RNA pull-
down assays have shown that these proteins strongly bind to
dsRNA and probably facilitate circRNA biogenesis by stabilizing
RNA base pairing (Li et al., 2017).
Other facilitators of the backsplicing process include the two
protein families called heterogeneous nuclear ribonucleoprotein
(hnRNPs) and serine-arginine (SR). Previous studies have
examined the role of hnRNPs in processes such as pre-mRNA
maturation, cellular transport, and stabilizing of mRNA (Geuens
et al., 2016). SR proteins also have multiple similar roles in
regulating gene expression (Shepard and Hertel, 2009). SR and
hnRNPs act together to circularize genes like Drosophila laccase2
(Kramer et al., 2015).
However, RBPs do not always accelerate the backsplicing
process and circularization. Both ADAR (adenosine deaminases
acting on RNA) and an RNA helicase called DHX9 can interact
with inverted ALUs repeats and unwind RNA base pairing and,
as a result, inhibit circularization (Ivanov et al., 2015; Aktaş et al.,
2017).
As mentioned earlier, backsplicing is not the only possible
mechanism of circRNA biogenesis. In the exon skipping (lariat)
model, following canonical splicing, the intermediate lariat
includes skipping exons endured backsplicing (Figure 2B). In
this potential biogenesis model, repeated sequences surrounding
the exons are unnecessary (Zaphiropoulos, 1997; Barrett et al.,
2015).
Two other probable mechanisms of circRNA’s biogenesis are
failure to debranch intron lariat (Figure 2C) and translocation
(Figure 2D). Translocations mainly occur in cancers and are
believed to be the potential biogenesis mechanisms (Guarnerio
et al., 2016; Wilusz, 2017). In addition to the items mentioned
earlier, the RNA pol II speed of synthesis also plays a decisive
role in a transcript’s fate. The higher the RNA pol II elongation
rate, the higher the ratio of circRNA to linear RNA synthesis.
As the percentage of RNA synthesis increases, the pairing of
complementary sequences is facilitated (Zhang et al., 2016).
CIRCRNAS PLAY FUNDAMENTAL
ROLES IN CELL OPERATION
Discovering facts such as circRNAs tissue-specific expression and
specific expression patterns during various development stages
has led researchers to investigate the functions of circRNAs.
Herein, we will give a brief overview of some of the main
functions that have been described for circRNAs.
MiRNA Sponging, Important but Not
General
MicroRNAs (miRNAs), RNA molecules with an approximate
length of 22 nucleotides, are involved in post transcription
Frontiers in Genetics | www.frontiersin.org 2 June 2021 | Volume 12 | Article 679446
fgene-12-679446 June 11, 2021 Time: 17:22 # 3
Yesharim et al. Practical Outlook of Circular RNAs
FIGURE 1 | Timeline showing the key events in the history of circRNAs discovery.
regulation of genes by preventing their target mRNAs’ translation
(Ambros, 2004). However, the regulatory network across the
transcriptome does not end up with mRNAs and miRNAs. In
2013, an investigation showed an ability of circRNAs in miRNA
sequestering, the phenomenon known as “miRNA sponging”
(Hansen et al., 2013; Figure 2F). The miRNA sponge capability
is not limited to circRNAs, and this feature is because of the
presence of MREs (MiRNA Response Elements). CircRNAs are
also referred to as competitive endogenous RNAs (ceRNAs) in
some published data through their ability to inhibit miRNAs’
regulatory function on mRNAs (Mitra et al., 2018; Smillie et al.,
2018). Although a significant number of published papers in the
field of circRNA rely on this possible role, this phenomenon
has been confirmed in just a small number of circRNAs (Dori
and Bicciato, 2019). CiRS-7 (also known as CDR1as), circSRY,
and circHIPK3 are three circRNAs involved in sponging miR-
7, miR-138, and miR-124, respectively (Hansen et al., 2013;
Zheng et al., 2016). CircRNAs indirectly affect extensive gene
networks. Each circRNA could have several miRNA bindings
sites, even for multiple different miRNAs, and each miRNA
could inhibit numerous mRNAs. To attribute the sponging
role to circRNAs, there must be evidence of miRNA-circRNA
co-localization. Additionally, co-expression of circRNA and
the related miRNA and the presence of MREs is necessary.
Furthermore, the circRNA’s length and the adequacy of their
expression abundance should be considered (Hansen et al., 2013;
Dori and Bicciato, 2019).
Circular RNAs Regulate Gene Expression
in Various Ways
CircRNAs are involved in several gene expression regulation
stages, such as transcription initiation and elongation, splicing,
and even translation. The three major known subtypes
of the circRNAs, exonic circRNAs (EcircRNA), intronic
circRNAs (CIRNA), and exon-intron circRNAs (EIciRNA), play
roles in this area.
The existence of 2’–5’ Phosphodiester-linked in CIRNAs
supports the hypothesis that the formation of this particular
subgroup of circRNAs happened because of lariat debranching
failure (Figure 2C). CIRNAs are enriched in the nucleus and
positively interact with phosphorylated RNA pol II during
elongation (Zhang et al., 2013; Figure 2E).
EIciRNAs, which contain both intron and exon in their
structure, are also accumulated in the nucleus and indirectly
regulate the RNA pol II by RNA-RNA interaction with the U1
snRNA subunit of spliceosome machinery and aid initiation of
transcription (Li Z. et al., 2015; Figure 2E). Both CIRNAs and
EIciRNAs apply for their regulatory role in a cis manner and
enhance their parental gene transcription. The trans-regulatory
role of these circRNAs is still a matter of debate.
CircRNAs are also involved in post-transcription regulation.
Except for the sponge role of circRNAs described earlier, circular
transcripts of a gene can prevent their linear counterparts’
efficient expression in other main ways. One way is the
competition between the linear and the circular form of a gene
in binding to translation-facilitating proteins. CircPABPN1, for
example, appears to reduce the binding of HuR protein -which
is known as translation promoter of PABPN1 mRNA- to its
linear counterpart and thus reduces the efficiency of translation
(Abdelmohsen et al., 2017). There is also a theory in which
CircRNAs can prevent protein buildup in a phenomenon called
“mRNA trapping.” CircRNAs like circFMN trap their linear
mRNA counterparts and block the translation start site, thus
protein synthesis (Chao et al., 1998; Figure 2G). Also, given that
both linear and circular forms of a gene originating from the
Frontiers in Genetics | www.frontiersin.org 3 June 2021 | Volume 12 | Article 679446
fgene-12-679446 June 11, 2021 Time: 17:22 # 4
Yesharim et al. Practical Outlook of Circular RNAs
FIGURE 2 | Scheme of main models of circRNAs biogenesis and circRNAs known cellular functions. (A) Generation of circRNAs via direct backsplicing and with the
help of RBPs. ADAR and DHX9 inhibit circRNAs formation by unwinding RNA base pairings. (B) Exon skipping model of circRNAs biogenesis. The intermediate lariat
formed in canonical splicing endures backsplicing. (C) The remained intron from splicing fails to debranch, leading to CIRNA formation. (D) F-circRNA formation
following translocation of chromosomes. (E) Transcription regulation of circRNAs. EIciRNA interacts with the U1 snRNP subunit of spliceosome machinery at the
beginning of transcription. CIRNA interacts with phosphorylated RNA polymerase II, facilitating elongation. (F) A circRNA sponging several miRNAs. (G) A circRNA
traps its linear counterpart and inhibits translation by blocking the translation start site. (H) Interaction of a circRNA with RBPs. (I) CircRNA acting as a scaffold,
facilitating enzyme and substrate reaction. (J) CircRNA containing IRES, coding protein. (K) Enrichment of various circRNAs in exosomes. Exosomal circRNAs are
potential biomarkers for various diseases.
same splice site, the biogenesis of circRNAs decreases the final
expression rate of linear RNA. It has been found that synthetic
cirRNAs are not only transmissible to the cytoplasm but also the
nucleus. Given that circRNAs are capable of regulating processes
in the nucleus, it is possible to use circRNAs to regulate processes
such as transcription and splicing (Jost et al., 2018).
Cell Directors in Close Contact With
circRNAs
CircRNAs interact with proteins, the important cellular directors,
in a variety of ways (Figures 2H,I). In addition to the
above-mentioned RBPs-circRNAs interactions during circRNAs
biogenesis, circRNAs can act as a protein transporter, subcellular
localizer and scaffold, facilitating protein-protein interactions.
Although bioinformatic studies were done based on
nucleotide sequences, the RBP chances of binding to circRNAs
are no more than linear forms, but the interaction seems stronger
(You et al., 2015).
Transfected cells with circAmotl1 showed increased AKT
levels in the nucleus, supporting the fact that circAmotl1 may be
involved in the nuclear translocation of AKT protein (Zeng et al.,
2017). Previous research has investigated the potential interaction
between circRNAs and proteins, denoted that circ-Foxo3 can
potentially act as a scaffold and facilitate the interaction of CDK2
and its inhibitor, p21. The ternary complex formed of circ-Foxo3,
p21, and CDK2, blocked the G1 to S phase transition of the cell
cycle by inhibiting the CDK2 and cyclin A/cyclin E interactions
(Du et al., 2016).
Evaluation of the role of circANRIL in atherosclerosis
and ribosomal RNA (rRNA) maturation process using mass
spectrometric and RNA immunoprecipitation (RIP) assays
showed two proteins; PES1 and NOP14 interacted mostly with
circANRIL, respectively (Holdt et al., 2016). Since the interaction
between PES1 and rRNA is essential for rRNA’s maturation
and ribosome formation, circANRIL binding to this member
of the PeBoW complex blocks the rRNA binding site and
consequently impair protein translation rate and cell growth
(Holdt et al., 2016).
Cells perform their vital functions through proteins. Proteins
interact with circRNAs for a variety of purposes. As can be
deduced from the above examples, some of the most important
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proteins are transported in the cell with the help of circRNAs.
Besides, proteins can interact effectively with other proteins and
molecules by binding to circRNAs as a platform. That is one of
the many reasons why the cell faces a crisis if mutations affect the
expression levels or RNA binding sites of circRNAs.
CircRNAs, Blurring Boundary Between
Coding and Non-coding World
CircRNAs are classified in the non-coding RNAs category.
However, evidence from mass spectrometry, ribosomal
footprinting, and CRISPR Cas9 based experiments indicated
this subtype of RNAs’ potential to produce proteins (Legnini
et al., 2017; Pamudurti et al., 2017; Yang Y.Y. et al., 2017). Two
general mechanisms are known to initiate protein synthesis:
cap-dependent and cap-independent [IRES (Internal Ribosome
Entry Site)-mediated] translation.
Since there is no 5′ cap structure in circRNAs, the probable
mechanism for circRNA translation is the cap-independent
(Chen and Sarnow, 1995), and it is done with the help of a
specific RNA element called IRES, which enables the interaction
of the 40S ribosomal subunits to the transcript (Merrick, 2004;
Figure 2J). The cap-independent translation is less effective than
the cap-dependent mechanism, but is more commonly used
during cellular stress like hypoxia and nutrient starvation, which
are common in cancer cells (Walters and Thompson, 2016).
The cap-independent mechanism promotes the translation of
proteins, such as transcription and growth factors, required for
cell survival (Walters and Thompson, 2016; Diallo et al., 2019;
Zhao et al., 2019). Studies have shown that sequences containing
methylated adenosine N6 (m6A) site at 5’ UTR can act as IRES
(Yang Y. et al., 2017).
M6A modifications involvement in processes such as mRNA
stability, splicing, and translation were approved, and now it
seems that m6A is also effective at the beginning of circRNAs
translation (Wang et al., 2014; Ma et al., 2016; Yang Y.
et al., 2017; Zhou et al., 2019). CircRNA-m6A-seq revealed
that m6A motifs are enriched in circRNAs. Yang Y. et al.
(2017) showed that circRNAs containing even a single m6A
motif are efficiently transcribed. Inserting m6a motifs before
the start codon of circRNA reporter results in efficient GFP
(green fluorescent protein) translation. The research revealed
that the production of proteins from circRNAs containing
m6A modification, which increased by heat shock, is similar
to the translation of mRNAs containing m6A modifications.
This study also demonstrated that the YTHDF3 plays an
indispensable role in this process as an m6A reader, which
interacts with the translation initiation factor eIF4G2 (Yang Y.
et al., 2017).
Several studies have shown the potential role of circRNAs
in protein production (Legnini et al., 2017; Zhang et al., 2018;
Liang et al., 2019). Also, tools have been developed to predict the
protein-coding potential of circRNAs. For example, CircCode is
a python-based tool capable of predicting protein production in
humans and Arabidopsis thaliana (Sun and Li, 2019).
It seems that by the advancement of technology in various
fields of science and the elimination of technical problems in this
area of research, more substantial evidence may be found to prove
the ability of circRNAs to code protein.
As can be seen from the examples mentioned earlier, circRNAs
are involved in different levels of cell metabolism. Understanding
these functions and their effect on maintaining cell homeostasis
can inspire new therapies. For example, targeting a circRNA,
which is multidimensionally involved in the pathogenesis of
a disease, can help effectively treat that disease. Even more,
designing and transfecting a circRNA that is capable of
adequately coding a tumor suppressor protein and also targeting
multiple onco-miRs can be a valuable treatment method.
CIRCRNA’S UNIQUE FEATURES
NOMINATED THEM AS THE ORIGIN
OF LIFE
Features like development and tissue specificity, self-catalyzing
capacity, and being conserve are among different species are
mentioned for circRNAs. However, perhaps the most essential
feature is the property acquired through their specific structure
(Xia et al., 2017). The closed ring structure of circRNAs leads to
the absence of a polyadenylated tail and 5’–3’ polarity. As a result,
they are highly stable because of their resistance to exonucleases,
including RNaseR (Suzuki et al., 2006). On average, the half-life
of circRNAs is 2.5 times more than their linear counterpart, and
this stability can last up to 48 h in cells (Jeck et al., 2013; Enuka
et al., 2015). Considering this capability, circRNAs could answer
the old question “where and how life begins?.” RNA molecules
were introduced as a possible origin of life because they could
have catalytic activity and store genetic information. However,
one critique of the “RNA World Hypothesis” is that RNAs are
not stable enough. Given the roles and properties mentioned for
circRNAs, especially the super stability feature of these molecules,
they can be considered as the potential candidate molecules
in initiating life (Demongeot and Moreira, 2007; Neveu et al.,
2013). However, answering such a comprehensive question is
very challenging since there is no direct evidence of this process.
Ideally, the primary circRNA should have a minimum number
of nucleotides to minimize the possibility of breakage. It must
also be capable of forming secondary structures such as hairpins
to increase both the molecule’s stability and have the surface
for interaction (Demongeot and Moreira, 2007). Putting aside
questions about how early nucleotides formed on Earth and
how nucleotides bind to each other in the “prebiotic pool,” this
hypothesis seems to be worth further investigation.
CIRCRNAS, POTENTIAL BIOMARKERS,
AND THE CHALLENGES AHEAD
CircRNAs have been suggested as potential biomarkers, as
their role in several intracellular molecular processes becomes
apparent. Exceptional stability among all types of RNAs
is perhaps the most important reason for using circRNAs
as biomarkers. CircRNAs, especially those originated from
exosomes (Figure 2K), can be detected in various body fluids,
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including saliva and serum, making it possible to diagnose and
predict the prognosis of different kinds of diseases in a non-
invasive or minimal-invasive manner (Li Y. et al., 2015). Some
circRNAs suggested as the biomarker in various cancers and non-
cancerous diseases with reported specificity and sensitivity are
listed in Tables 1, 2.
RNA-seq and microarray are the two common high
throughput methods for analyzing RNA expression profiles.
Using the RNA-seq method seems to be more challenging and
less efficient than microarray in the field of circRNAs. Using
different library preparation methods, such as size selection or
the RNA-seq reading depth, can lead to the loss of small-sized
and low-abundant circRNAs data, respectively. Besides, although
various algorithms have been developed for circRNA detection
in RNA-seq data, none of them seems to be as efficient as they
should be, and there is a slight overlap between the results of
different algorithms (more details on Szabo and Salzman, 2016).
It was demonstrated that microarrays are about 10 times more
capable of detecting circRNAs than RNA-seq with an average
of 20 million reads depth. However, it is impossible to detect
unknown circRNAs using microarrays (Li et al., 2018).
Another factor making the study of circRNAs demanding is
the lack of a unit and standard nomenclature system (Franz
et al., 2018). Various databases and articles use different naming
methods, and converting names to each other is time-consuming
and complicated; therefore, there is an urgent need for a single
nomenclature system. Some of the most widely used databases for
circRNAs and the information they provide is listed in Table 3.
THERAPEUTIC UTILITY OF CIRCRNAS
CircRNAs are molecules with the potential to treat a wide range
of diseases. CircRNA-based treatments can be divided into two
general categories. Not only can they be used as a therapeutic
target, but it is also possible to take advantage of engineered
circRNAs as medicinal operators (Figure 3 summarized some
potential applications of circRNAs in the treatment of diseases).
Imagine a circRNA that is known to play a significant role in
the exacerbation of a disease. One therapeutic approach can be
to knockdown this circRNA with the help of RNA interference
(RNAi) (Figure 3A). siRNA’s must be designed to target back-
spliced junction; thus, the linear counterpart remains intact
(Santer et al., 2019). Studies confirmed that using siRNAs-based
knockdown of circRNAs involving various diseases’ pathogenesis
will be a promising approach. In vitro assays demonstrated
that circ-EIF4G3 and circ-0023642 knockdown would suppress
cell proliferation and invasion of gastric cancer (Zhou et al.,
2018; Wang Q. et al., 2019). Similar experiments in knockdown
of circ-VAPA and circ_ANF609 have similar colorectal and
nasopharyngeal carcinoma results, respectively (Yu, 2020; Zhang
et al., 2020).
Fusion circRNAs (f-circRNAs), primarily generated in
chromosomal translocations during tumorigenesis, are potential
cancer treatment targets. The formation of circRNAs can
lead to drug resistance, cellular transformation, and other
tumor-related hallmarks (Guarnerio et al., 2016). F-circRNAs
knockdown would be a good choice for cancer cell-specific
targeting (Figure 3A). Sometimes circRNAs knockdown can
be used as a co-medication. A recently published study found
that circRACGAP1 suppression could be used to reduce the
toxic effects of apatinib (a drug that has anti-cancer effects by
inhibiting VEGFR-2 tyrosine kinase). CircRACGAP1 enables
autophagy-related gene 7 (ATG7) overexpression by sponging
miR-3657. Inhibition of circRACGAP1 leads to cell apoptosis
instead of autophagy, which sometimes causes cancer cells to
survive under environmental stress (Yun and Lee, 2018; Ma
et al., 2020).
Another role of circRNAs, which make them suitable
candidates for disease treatment, lies in their ability to act as
miRNA sponges (Figure 3B). A recently in vivo research result
demonstrated that a small dose of unmodified circRNA could
sponge two miRNAs involved in cardiac hypertrophy, thereby
preventing heart failure (Lavenniah et al., 2020). It has also been
shown that transfection of synthetic circRNA named scRNA21
increases the level of miR-21 target proteins such as Daxx by
efficiently sponging miR-21 and inhibiting the proliferation of
gastric cancer cells (Liu et al., 2018).
Perhaps the most revolutionary circRNA-based treatment
lies in their stability and protein-coding capacity. Obtaining
a stable expression of an exogenous protein is one of the
main issues scientists have been facing. However, using mRNAs
for this purpose has the advantage of being safer than DNA
manipulation, but achieving adequate and stable expression has
always been a challenge for researchers. Considering the potential
ability of circRNAs to be translated and their high stability makes
them applicable candidates. Researchers found an exogenous
circRNA could produce much higher amounts of protein than
unmodified linear mRNA and even modified linear mRNA
counterparts (Figure 3D; Wesselhoeft et al., 2018). Unmodified
circRNAs made from cloned self-splicing intron were transfected
using a cationic lipid reagent. The protein production half-life of
the highly purified circRNA was approximately two times higher
than linear mRNA (Wesselhoeft et al., 2018).
IMMUNE RESPONSE TOWARD
EXOGENOUS CIRCRNAS
The ability of circRNAs in the prolonged production of proteins
highly suites them as protein expression vectors and favorable in
treating many diseases. Nevertheless, there are still fundamental
questions to be answered. How does the immune system respond
to exogenous circRNAs? Do circRNAs trigger the immune system
as much as linear RNAs?
The truth is that researcher’s findings seem contradictory.
A study done before investigating the ability of engineered
circRNAs in protein production regarded exogenous circRNAs
as an immunogenic agent. Chen Y.G. et al. (2017) showed that
transfection of HeLa cells with RNAse R purified circRNAs
results in overexpression of innate immunity genes like RIG-I
(retinoic-acid-inducible gene-I) up to 500-fold. The role of RIG-I
in controlling viral infections had been identified earlier. RIG-
I triggers the innate immune system after recognizing dsRNA



















TABLE 1 | Potential circRNA biomarkers in different types of cancers.
CircRNA ID Alias Cancer type Sensitivity Specificity Biological
sample
Regulation Clinicopathologic correlation References






Up Tumor size Tian et al., 2019
hsa_circ_0006988 hsa_circRNA_100799 Pancreatic cancer 57.38% 70.49% Tissue and
plasma
















Venus invasion, Metastasis Lü et al., 2017
hsa_circ_0000190 hsa_circRNA_000190 Gastric cancer 72.1% 68.3% Tissue and
plasma
Down Tumor diameter, Lymphatic
metastasis, Distal metastasis
Chen S. et al., 2017
hsa_circ_0067582 hsa_circRNA_103482 Gastric cancer 66.6% 61.2% Tissue Down Tumor diameter Yu et al., 2019
hsa_circ_0065149 hsa_circRNA_103342 Gastric cancer 79.2% 61.5% Tissue Down Larger tumor diameter, Perineural
invasion
Shao et al., 2019
hsa_circ_0005556 hsa_circRNA_102631 Gastric cancer 64.0% 82.0% Tissue Down Differentiation, TNM stage, Lymphatic
metastasis
Yang et al., 2019
hsa_circ_002059 hsa_circRNA_020596 Gastric cancer 81.0% 62.0% Tissue Down TNM stage, Distal metastasis Li P. et al., 2015
hsa_circ_0000467 hsa_circRNA_101231 Gastric cancer 70.5% 64.8% Tissue Up Lymphatic invasion, TNM stage Lu et al., 2019
hsa_circ_0000567 hsa_circRNA_101436 Colorectal cancer 83.3% 76.4% Tissue Down Tumor size, Lymph metastasis, Distal
metastasis, Tumor node metastasis,
TNM stage











Proliferation Liu X.X. et al., 2019
hsa_circ_0013958 hsa_circRNA_100323 Lung adenocarcinoma 75.5% 79.6% Tissue Up TNM stage, Lymphatic metastasis Zhu et al., 2017
hsa_circ_0137287 − Papillary thyroid carcinoma 79.2% 90.0% Tissue Down Extrathyroidal extension, Lymph node
metastasis, T stage, Larger tumor
diameter
Lan et al., 2018
hsa_circ_0003998 hsa_circRNA_003998 Hepatocellular carcinoma 84.0% 80.0% Tissue Up AFP level, Larger tumor diameter,
Microvascular invasion, Differentiation
Qiao et al., 2019
hsa_circ_0004018 hsa_circRNA_101940 Hepatocellular carcinoma 71.6% 81.5% Tissue Down AFP level, Tumor diameters,
Differentiation,
Tumor-node-metastasis, TNM stage
Fu et al., 2017
hsa_circ_0128298 − Hepatocellular carcinoma 67.4% 80.5% Tissue Up Vascular cancer embolus, Lymphatic
metastasis, Organ metastasis
Chen et al., 2018
Hsa_circ_0001649 hsa_circRNA_104206 Hepatocellular carcinoma 81.0% 69.0% Tissue Down Tumor size, Tumor embolus,
Metastasis
Qin et al., 2016
hsa_circ_0072387 hsa_circRNA_103829 Oral squamous cell carcinoma 71.4% 69.8% Tissue Down Tumor diameters, T stage, TNM stage Dou et al., 2019




































TABLE 2 | Potential circRNA biomarkers in non-cancerous diseases.
CircRNA IDa Alias Disease Sensitivity Specificity Biological sample Regulation Probable mechanism of actionb References
hsa_circ_0007121 − Preeclampsia 77.3% 70.3% Plasma Down Act in apoptosis, Wnt-signaling, and
HIF-1 pathways
Bai et al., 2018
hsa_circ_0000479 hsa_circRNA_000479 Systemic lupus
erythematosus (SLE)
80.0% 71.1% Peripheral blood
mononuclear cells
Up Not included Luo et al., 2020
hsa_circ_0044235 hsa_circRNA_044235 Systemic lupus
erythematosus (SLE)
70.0% 100% Peripheral blood
mononuclear cells













Up possible interaction with miR-18a-3p
possible interaction miR-203a-3p and
miR-143-3p
Su et al., 2019
hsa_circ_0063411 hsa_circRNA_063411 Amyotrophic Lateral
Sclerosis (ALS)
100% 100% Plasma Up possible interaction with hsa-miR-647 Dolinar et al., 2019
hsa_circ_0000700 hsa_circRNA_001937 Active Tuberculosis 85.0% 77.5% Peripheral blood
mononuclear cells
Up possible interaction with 6 miRNAs
(includes miR-22-5p, miR-26b-3p,
miR-10b-3p, miR-376a-5p and
miR-597-3p) MiR-26b act in the
inflammatory response by modulating the
NFκB pathway through targeting PTEN.
Huang et al., 2018
hsa_circ_0002453 circRNA_002453 Lupus nephritis 90.0% 84.1% Plasma Up Not included Ouyang et al., 2018
hsa_circ_0126991 − Essential
Hypertension
72.4% 67.3% Plasma Up Act in cell apoptosis and the Robo
receptor signaling pathway and related to
intercellular adhesion factors.













Up possible interaction with hsa-miR-378d
and hsa-miR-26b-3p
Luo et al., 2019a
hsa_circ_0054633 − Type 2 Diabetes
Mellitus (T2DM)
55.0% 85.0% Peripheral blood
mononuclear cells
Up Possible role in the biological processes
like cell cycle and mitotic cell cycle arrest
and catabolism of molecules.
Li et al., 2016
hsa_circ_0068481 hsa_circRNA_103544 Pulmonary arterial
hypertension
74.39% 98.7% Serum UP Not included Zhang et al., 2019
hsa_circ_0084021 hsa_circRNA_104597 Schizophrenia 84.31% 86.4% Peripheral blood
mononuclear cells




Yao et al., 2019
hsa_circ_0032131 − Osteoarthritis 90.0% 65.0% Peripheral blood
mononuclear cells











Up Possible role in metabolic pathways and
PI3K-Akt signaling pathways.
Wang L. et al., 2019
hsa_circ_0124644 − Coronary artery
disease
86.7% 76.7% Peripheral blood
mononuclear cells
Up Possible interaction with miR-10a-5p Zhao et al., 2017
aCircRNA ID in circBase database.




































TABLE 3 | Some of the most useful circRNA databases which are constantly updated.
Database/webtool Website Data provided and main capabilities Covered species References
circBase http://www.circbase.org/ Unique circRNA ID, position and genomic range of circRNAs, can be searched
by three different ways: (1) Simple search, (2) List search and (3) Table browser
Homo sapiens, Mus musculus,
Caenorhabditis elegans, Latimeria
Glažar et al., 2014
circRNADb http://reprod.njmu.edu.cn/
circrnadb/
CircRNAs with protein coding potential by considering ORF and IRES elements,
can also be browsed by 11 different cell type and tissue. General information
like genomic position, best transcript id and etc. provided




http://gb.whu.edu.cn/TSCD Validated tissue specific circRNAs
potential related miRNAs and proteins considering MREs and protein binding
sites, conservation among species




http://gb.whu.edu.cn/CSCD Cancer specific circRNAs
Function prediction considering protein coding capacity and miR sponging
potential
cellular location
















Function description (validated or predicted miR or RBPs interaction)
Expression pattern
Homo sapiens Fan et al., 2018
TRCirc http:
//www.licpathway.net/TRCirc/
Information on transcription regulatory function of circRNAs
based on ChIP-seq data
visualization of TF–circRNA regulation network and Histogram of expression of
circRNAs are possible
Homo sapiens Tang et al., 2019
WebCircRNA https:
//rth.dk/resources/webcircrna/
Predict the circRNA production possibility based on sequence and conservation All species Pan et al., 2018
CircInteractome https:
//circinteractome.nia.nih.gov/
circRNA-miR and circRNA_RBP predicting tool
Primer and siRNA design capability
Homo sapiens Panda et al., 2018
CircFunBase http:
//bis.zju.edu.cn/CircFunBase/




Homo sapiens, Macaca mulatta and
Arabidopsis thaliana
Meng et al., 2019
Circbank http://www.circbank.cn/ Use the naming system for circRNAs based on the host gene
Predict miR sponging and protein coding capability, m6A methylation,
conservation across species
Homo sapiens Liu M. et al., 2019
circAtlas http://circatlas.biols.ac.cn/ Conservation information of circRNAs across the species, tissues and
individuals
Functional annotation of the circRNAs based on miRNA interaction and
RNA-binding protein (RBP) interaction data.
The database can be searched in different ways like genomic position,
ensemble gene ID and different circRNA names.
Si$x vertebrates including
Homo sapiens, Macaca mulatta, Mus
musculus, Rattus norvegicus, sus
scrofa, Gallus gallus
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FIGURE 3 | Scheme of some the possible treatment approaches based on the characteristics of circRNAs. (A) Targeting the backsplice junction of onco-circs or
f-circs by siRNAs leads to the degradation of these harmful circRNAs. (B) Exclusive circRNAs designed to sequester/sponge oncogenic miRNAs. (C) Utilizing the
possible immunogenic properties of circRNAs as an adjuvant. (D) Despite the lower biogenesis of circRNAs than linear RNAs, more stable translation can be
achieved due to the high stability of circRNAs. This feature makes circRNAs ideal for protein replacement therapies.
and 5′ triphosphate (Kell and Gale, 2015). CircRNAs lack 5′
triphosphate, so what triggers innate immunity, and how RIG-
I sense endogenous circRNAs from exogenous ones? (Chen
Y.G. et al., 2017) proved by an experiment that splicing of a
circRNA with human introns in human cells does not induce
RIG-I, and this result is independent of circRNA exon sequence.
These results stated that RBPs associated with human-specific
splicesome mark circRNAs as “self ” or “non-self.” Nevertheless,
two separate studies, both conducted by Wesselhoeft et al. (2018,
2019), assumed that the innate immune system provocation
was only because of circRNAs contamination with other types
of RNAs, and the use of ultra-pure circRNAs showed no
significant sign of innate immune system provocation. Injection
of RNaseR and phosphatase treated circRNAs, purified by HPLC
into mice adipose tissue, did not show cytokine secretion.
Also, the protein expression remained stable, supporting the
ability of circRNAs to perform protein replacement therapy
(Ma et al., 2016).
It is not the end of the story. In another research, Chen
et al. (2019) confirmed their findings of circRNAs immunizing
capacity. In this study, even though using HPLC purified
circRNAs, immune system stimulation was still observed.
Subcutaneous injection of exogenous circRNA results in
dendritic cell activation and, as a result, indirect activation of
T cells, which means not only the innate immune system but
also the acquired immunity is triggered by exogenous circRNAs.
These findings introduce another therapeutic potential of
circRNAs to act as an adjuvant (Figure 3C). They also described
the role of m6A modification patterns in distinguishing between
endogenous and exogenous circRNAs. M6A modifications
prevent RIG-I binding to circRNAs and, as a result, activation
of the immune response. Experiments indicate that circRNAs
from different origins (i.e., human vs. phage) have different m6A
modification patterns at 3′ of back-splice junction and, therefore,
different immunity response.
Differences in these researches findings may be attributed
to details in the experiment’s design, such as cell types or the
used reagents (Basavappa and Cherry, 2019). Further studies
are needed to confirm each of these results and explain the
underlying mechanisms of differences.
DISCUSSION
For years, circRNAs were known as a “by-product of splicing”
rather than a subspecies of RNAs with independent roles.
However, in recent years series of functions have been
defined for them.
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This review summarized the current and potential
applications of circRNAs based on their various functions and
features. CircRNAs have multiple roles in biological processes,
like gene expression regulation, interacting with proteins for
different purposes, and coding proteins. Most of the published
papers focused on the post transcription regulation of circRNAs,
miR sponging. However, researchers should consider items such
as sufficient circRNA amount, co-expression with the target miR,
and the ratio between circRNA and target miRs in cases where the
“sponging” capacity has not been investigated by experimental
methods (Dori and Bicciato, 2019). In addition to the fact that
circRNAs have various roles in the pathogenesis of various
diseases, the stability and presence of circRNAs in body fluids like
plasma and saliva have made them ideal diagnostic/prognostic
biomarkers, and even several clinical trials are underway
in this regard (ClinicalTrials.gov number: NCT04584996;
NCT03170830). However, there are still challenges that need
to be addressed to expedite and facilitate such studies. RNA-seq
and microarray are among the high-throughput technologies
that are used to screen differentially expressed circRNAs in
different conditions. RNA-seq can evaluate the expression levels
of unknown circRNAs. However, different analysis algorithms
and even different library preparation methods lead to different
results. To get the most out of this method, developing a gold
standard for library preparation and bioinformatics analysis
pipelines is highly recommended (Engström et al., 2013; Szabo
and Salzman, 2016). Although microarray seems to be more
efficient than RNA-seq, however, this method is limited to known
circRNAs, and also more initial amount of RNA is needed
(Li et al., 2018).
In addition to the role that circRNAs can play in the diagnosis
and management of diseases, various features of circRNAs
can also be used in the treatment of diseases. One possible
treatment approach is to reduce the expression of circRNAs
such as f-circRNAs and onco-circRNAs using siRNA designed
for backspliced junction (Guarnerio et al., 2016). The alternative
method for suppressing the circRNA expression is the use of
CRISPR/CAS9. Adequate care must be taken in the use of
the CRISPR/CAS9 system. Given that most circRNAs have a
common origin with their linear counterpart, this method can
only be used to remove the complementary sequences required
for the biogenesis of circRNAs (Zhang et al., 2016). Moreover,
engineered circRNAs can be used to sponge the disease-related
miRNAs. Although anti-miRNA drugs such as Miravirsen (a
locked-nucleic-acid (LNA)/DNA-mixmer oligonucleotide use to
target HCV-related miRNA, miR22) have already been designed,
LNA-based drugs show side effects related to the accumulation of
unmetabolizable LNA nucleotides. Since the elimination cycle of
circRNAs is naturally embedded in the cells, such complications
are unlikely to occur (Janssen et al., 2013; Jost et al., 2018).
Another potential revolutionary circRNA-based treatment
is achieving stable and efficient protein production in cells,
regarding the resistance of circRNAs toward many ribonucleases.
Nevertheless, further research needs to be done to establish the
immune system’s precise mechanism of action toward exogenous
circRNAs. If the immune system is not stimulated, stable protein
expression is achieved. But if the activation of the immune system
occurs, as happened in Chen et al. (2019) investigation, this event
can be used positively, and circRNAs can be used as an adjuvant.
It is possible that by eliminating technical shortcomings and
expanding knowledge in this area, circRNAs, once considered
a by-product of splicing, shed new light on diagnosing and
treating diseases.
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